Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.38 |
| ▸ | PGR | P06401 | 7/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170051 | 0.88 | NR3C1 (0.39) | NR3C1PGRNR3C2 | |
| SCHEMBL4167085 | 0.79 | CYP1A2 (0.42) | PDE4BNR3C1PGRNR3C2CYP1A2 | |
| SCHEMBL12534236 | 0.78 | NR3C1 (0.45) | NR3C1PGRNR3C2 | |
| SCHEMBL5363258 | 0.77 | NR3C1 (0.46) | NR3C1PGRNR3C2 | |
| SCHEMBL5355509 | 0.77 | NR3C1 (0.43) | NR3C1PGRNR3C2 | |
| SCHEMBL5355518 | 0.77 | NR3C1 (0.43) | NR3C1PGRNR3C2 | |
| SCHEMBL303903 | 0.76 | NR3C1 (0.46) | NR3C1PGRNR3C2 | |
| SCHEMBL4167063 | 0.75 | NR3C1 (0.33) | NR3C1PGRNR3C2 | |
| SCHEMBL4168320 | 0.73 | NR3C1 (0.49) | NR3C1PGRNR3C2 | |
| SCHEMBL4442883 | 0.72 | NR3C1 (0.39) | PDE4BNR3C1PGRNR3C2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | REGAN JOHN ROBINSON | 2009-07-09 | — | — | US | disclosed |
| EP-1730145-A1 | ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| WO-2005095401-A1 | ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176807-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | NR3C1, NR3C2, MC2R | PDE4B 1100/4885NR3C1 1/4885PGR 71/4885 |
| US-20050234091-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, MC2R, NR3C2 | PDE4B 1186/4885NR3C1 1/4885PGR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.